A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of ALXn1007 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2013
At a glance
- Drugs ALXN 1007 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jul 2013 Dosing has been completed, according to the Alexion Q2 report.
- 04 Jun 2013 Planned End Date changed from 1 Feb 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.